VNDA — Vanda Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $328.82m
- -$65.32m
- $192.64m
- 80
- 49
- 87
- 83
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.65 | ||
| Price to Tang. Book | 0.84 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.5% | ||
| Return on Equity | -0.91% | ||
| Operating Margin | -14.18% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 227.19 | 248.17 | 268.68 | 254.38 | 192.64 | 194.5 | 232.4 | -0.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +343.34 | -75.56 | +65.94 | -87.11 | -60.42 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Directors
- H. Thomas Watkins NEC (68)
- Mihael Polymeropoulos CEO (61)
- Kevin Moran CFO (37)
- Joakim Wijkstrom SVP (55)
- Timothy Williams SVP (45)
- Gunther Birznieks SVP (52)
- Phaedra Chrousos IND (41)
- Richard Dugan IND (79)
- Stephen Mitchell IND (69)
- Anne Ward IND (49)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- November 13th, 2002
- Public Since
- April 12th, 2006
- No. of Shareholders
- 9
- No. of Employees
- 203
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 58,198,273
- Address
- SUITE 300E, 2200 PENNSYLVANIA AVE NW, WASHINGTON, 20037
- Web
- https://www.vandapharma.com/
- Phone
- +1 2027343400
- Contact
- Kevin Moran
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for VNDA
Q3 2024 Vanda Pharmaceuticals Inc Earnings Release
Similar to VNDA
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Vanda Pharmaceuticals share price?
As of Today at 23:59 UTC, shares in Vanda Pharmaceuticals are trading at $6.12. This share price information is delayed by 15 minutes.
How has the Vanda Pharmaceuticals share price performed this year?
Shares in Vanda Pharmaceuticals last closed at $6.12 and the price had moved by -4.82% over the past 365 days. In terms of relative price strength the Vanda Pharmaceuticals share price has underperformed the S&P500 Index by -24.26% over the past year.
What are the analyst and broker recommendations for Vanda Pharmaceuticals?
The overall consensus recommendation for Vanda Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Vanda Pharmaceuticals dividend yield?
Vanda Pharmaceuticals does not currently pay a dividend.
Does Vanda Pharmaceuticals pay a dividend?
Vanda Pharmaceuticals does not currently pay a dividend.
When does Vanda Pharmaceuticals next pay dividends?
Vanda Pharmaceuticals does not currently pay a dividend.
How do I buy Vanda Pharmaceuticals shares?
To buy shares in Vanda Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vanda Pharmaceuticals?
As of the previous close price of $6.12, shares in Vanda Pharmaceuticals had a market capitalisation of $356.17m.
Where are Vanda Pharmaceuticals shares listed?
Here are the trading details for Vanda Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: VNDA
What kind of share is Vanda Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Vanda Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vanda Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Vanda Pharmaceuticals is $5.21. That is 14.87% below the last closing price of $6.12.
Analysts covering Vanda Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.06 for the next financial year.
What is the trend in the Vanda Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vanda Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +34.7%.
As of the last closing price of $6.12, shares in Vanda Pharmaceuticals were trading +39.77% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vanda Pharmaceuticals PE Ratio?
The Vanda Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vanda Pharmaceuticals?
Vanda Pharmaceuticals' management team is headed by:
- H. Thomas Watkins - NEC
- Mihael Polymeropoulos - CEO
- Kevin Moran - CFO
- Joakim Wijkstrom - SVP
- Timothy Williams - SVP
- Gunther Birznieks - SVP
- Phaedra Chrousos - IND
- Richard Dugan - IND
- Stephen Mitchell - IND
- Anne Ward - IND